<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192813</url>
  </required_header>
  <id_info>
    <org_study_id>SCOPE II</org_study_id>
    <nct_id>NCT03192813</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Comparison Of Two TAVI Systems in a Prospective Randomized Evaluation II</brief_title>
  <acronym>SCOPE II</acronym>
  <official_title>Safety and Efficacy Comparison Of Two TAVI Systems in a Prospective Randomized Evaluation II: A Randomized, Controlled, Non-inferiority Trial Evaluating Safety and Clinical Efficacy of the Symetis ACURATE Neo Compared to the Medtronic Evolut R Bioprosthesis in Transfemoral Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ceric Sàrl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Symetis SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ceric Sàrl</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current care randomized clinical trial comparing the CE marked Symetis ACURATE neo™ Aortic
      Bioprosthesis and ACURATE TF™ Transfemoral Delivery System with the CE marked Medtronic
      CoreValve Evolut R TAVI system (or any future CE-marked CoreValve versions).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter aortic valve implantation (TAVI) is an established and valuable treatment
      option for patients with severe symptomatic aortic stenosis and at high surgical risk for
      aortic valve replacement. The use of TAVI is rapidly expanding worldwide and its indications
      are widening into intermediate and lower risk populations. However, device comparisons by use
      of randomized trials are scarce in particular for newer generation transcatheter valves.

      The Symetis ACURATE neo™, a self-expanding transcatheter valve delivered via transfemoral
      access, is a second-generation device that gained CE mark approval in June 2014.

      The SCOPE-II trial will compare the safety and performance of the Symetis ACURATE neo™ with
      the self-expanding Medtronic Evolut R system, a widely used and well-established
      transcatheter heart valve, which obtained CE mark in 8NOV2006 and HAS approval on 13JAN2015.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of all-cause mortality or stroke rates</measure>
    <time_frame>1 year</time_frame>
    <description>The primary objective is to compare the composite of all-cause mortality or stroke rates at 1 year (powered for non-inferiority).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New permanent pacemaker rate</measure>
    <time_frame>30 days</time_frame>
    <description>The first secondary objective is to compare the new permanent pacemaker rate at 30 days (powered for superiority).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve malpositioning at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Valve malpositioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural myocardial infarction at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Peri-procedural myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Tamponade at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiac Tamponade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation of multiple valves (TAV-in-TAV deployment) at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Implantation of multiple valves (TAV-in-TAV deployment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annular rupture/dissection at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>- Annular rupture/dissection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular perforation at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>- Left ventricular perforation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion to open heart surgery at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>- Conversion to open heart surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-procedural mortality (during index procedure)</measure>
    <time_frame>Procedurally</time_frame>
    <description>- Intra-procedural mortality (during index procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural mortality (up to 72 hours after procedure)</measure>
    <time_frame>Procedurally and up to 72 hours post-procedurally</time_frame>
    <description>- Procedural mortality (up to 72 hours after procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (cardiac/non-cardiac) at 30 days and 1 year</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>- Mortality (cardiac/non-cardiac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All stroke (disabling/non disabling) at 30 days and 1 year</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>- All stroke (disabling/non disabling)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause mortality or disabling stroke at 30 days and 1 year</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>- Composite of all-cause mortality or disabling stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for valve-related symptoms or worsened congestive heart at 30 days and 1 year</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>- Hospitalization for valve-related symptoms or worsened congestive heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life-threatening/major bleeding at 30 days and 1 year</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>- Life-threatening/major bleeding (BARC 3b or more)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction at 30 days and 1 year</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>- Myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve related dysfunction requiring repeat procedure at 30 days and 1 year</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>- Valve related dysfunction requiring repeat procedure (BAV, TAVI or SAVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocarditis at 30 days and 1 year</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>- Endocarditis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve thrombosis at 30 days and 1 year</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>- Valve thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New AV-conduction disturbances at 30 days and 1 year</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>- New AV-conduction disturbances (LBBB only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New pacemaker implantation at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>- New pacemaker implantation at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any arrhythmia resulting in hemodynamic instability or requiring therapy at 30 days and 1 year</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Any arrhythmia resulting in hemodynamic instability or requiring therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VARC-2 combined endpoints at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of device success, early safety, clinical efficacy and time-related valve safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-related valve safety at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>Time-related valve safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoint (1)</measure>
    <time_frame>Post-procedurally [day 1 to 7], at 30 days, 1 year</time_frame>
    <description>- Structural valve deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoint (2)</measure>
    <time_frame>Post-procedurally [day 1 to 7], at 30 days, 1 year</time_frame>
    <description>- Prosthetic aortic valve stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoint (3)</measure>
    <time_frame>Post-procedurally [day 1 to 7], at 30 days, 1 year</time_frame>
    <description>- Patient prosthesis mismatch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoint (4)</measure>
    <time_frame>Post-procedurally [day 1 to 7], at 30 days, 1 year</time_frame>
    <description>- Aortic regurgitation (grading), proportion of more than mild regurgitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoint (5)</measure>
    <time_frame>Post-procedurally [day 1 to 7], at 30 days, 1 year</time_frame>
    <description>- Intended valve performance: No prosthesis mismatch, mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3 m/s, without moderate or severe prosthetic valve aortic regurgitation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoint (6)</measure>
    <time_frame>Post-procedurally [day 1 to 7], at 30 days, 1 year</time_frame>
    <description>- Systolic LV ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoint (7)</measure>
    <time_frame>Post-procedurally [day 1 to 7], at 30 days, 1 year</time_frame>
    <description>- LV diastolic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoint (8)</measure>
    <time_frame>Post-procedurally [day 1 to 7], at 30 days, 1 year</time_frame>
    <description>- Left atrial volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoint (9)</measure>
    <time_frame>Post-procedurally [day 1 to 7], at 30 days, 1 year</time_frame>
    <description>- Right ventricular (RV) dimension and function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoint (10)</measure>
    <time_frame>Post-procedurally [day 1 to 7], at 30 days, 1 year</time_frame>
    <description>- Right atrial (RA) area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoint (11)</measure>
    <time_frame>Post-procedurally [day 1 to 7], at 30 days, 1 year</time_frame>
    <description>- RV/RA-ratio and estimated systolic pulmonary arterial pressure</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">764</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Symetis ACURATE neo™ transfemoral TAVI system</arm_group_label>
    <description>Patient assigned to this group will be implanted with Symetis ACURATE neo™ transfemoral TAVI system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medtronic CoreValve Evolut R TAVI System</arm_group_label>
    <description>Patient assigned to this group will be implanted with Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Symetis ACURATE neo™ transfemoral TAVI system</intervention_name>
    <description>Symetis ACURATE neo™ transfemoral TAVI system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).</description>
    <arm_group_label>Symetis ACURATE neo™ transfemoral TAVI system</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic CoreValve Evolut R TAVI System</intervention_name>
    <description>Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System (or any future CE-marked Corevalve versions): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).</description>
    <arm_group_label>Medtronic CoreValve Evolut R TAVI System</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        764 patients presenting with severe symptomatic aortic stenosis with the indication for
        TAVI, as agreed by the Heart Team. If all eligibility criteria and none of the exclusion
        criteria are fulfilled, patients will be allocated in a 1:1 ratio to either the Symetis
        ACURATE neo™ or the Medtronic CoreValve Evolut R (or any future CE-marked CoreValve
        versions) by permuted block randomization.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with severe symptomatic aortic stenosis defined by a mean aortic gradient &gt; 40
             mmHg or peak jet velocity &gt; 4.0 m/s or an aortic valve area (AVA) &lt; 1cm2 or AVA
             indexed to body surface area (BSA) of &lt;0.6 cm2/m2

          -  Patient is symptomatic (heart failure with New York Heart Association (NYHA)
             Functional Class &gt; I, angina or syncope)

          -  Patients are considered at high risk for mortality with conventional surgical aortic
             valve replacement as assessed by a Heart Team consisting of a cardiologist and surgeon
             or as confirmed by a logistic EuroSCORE I &gt; 20% and / or STS score &gt; 10%.

          -  Aortic annulus diameter ranging from 21 to 26mm and perimeter rage from 66 - 81.7mm ,
             based on ECG-gated multi-slice computed tomographic measurements. Findings of TTE, TEE
             and conventional aortography should be integrated in the anatomic assessment.

          -  Arterial aorto-iliac-femoral axis suitable for transfemoral access as assessed by
             conventional angiography and/or multi-detector computed tomographic angiography
             (access vessel diameter ≥ 6mm)

          -  Patient understands the purpose, the potential risks as well as benefits of the trial
             and is willing to participate in all parts of the follow-up

          -  Patient age 75 years or older

          -  Patient has given written consent to participate in the trial

        Exclusion Criteria:

          -  Severely reduced left ventricular (LV) function (ejection fraction &lt;20%)

          -  Pre-existing prosthetic heart valve in aortic and/or mitral position

          -  Participation in another trial, which would lead to deviations in the preparation or
             performance of the intervention or the post-implantation management from this protocol

          -  Severe coagulation conditions

          -  Inability to tolerate anticoagulation therapy

          -  Contraindication to contrast media or allergy to nitinol

          -  Active infection, including endocarditis

          -  Congenital aortic stenosis or unicuspid or bicuspid aortic valve

          -  Non-valvular aortic stenosis

          -  Hypertrophic obstructive cardiomyopathy

          -  New or untreated echocardiographic evidence of intracardiac mass, thrombus, or
             vegetation

          -  Non-calcific acquired aortic stenosis

          -  Severe eccentricity of calcification

          -  Anatomy not appropriate for transfemoral implant due to size, disease and degree of
             calcification or tortuosity of the aorta or ilio-femoral arteries

          -  Severe mitral regurgitation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corrado Tamburino, Prof, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Division and Cardio-Thoracic &amp; Vascular Department, Ferrarotto &amp; Policlinico Hospitals, University of Catania, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Hengstenberg, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Department Deutsches Herzzentrum München, Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabine Bleiziffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiac Surgery Department Deutsches Herzzentrum München, Munich, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Murielle Bierlein, PhD</last_name>
    <phone>+33176739259</phone>
    <email>mbierlein@cerc-europe.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laure Morsiani, PhD</last_name>
    <phone>+33176739236</phone>
    <email>lmorsiani@cerc-europe.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Center, Rigshospitalet, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Sondergaard, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oulun University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timo Makikallio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Brest Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine Gilard, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Garot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Tchetche, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jochen Börgermann, Prof, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Smita Scholtz, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jörg Kempfert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Brandenburg, Immanuel Klinikum Bernau</name>
      <address>
        <city>Bernau bei Berlin</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Butter, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.-Johannes-Hospital</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helge Möllmann, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Krankenhaus Essen</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Wolf, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Christian Schulze, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig - Universitätsklinik</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Axel Linke, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Herz- &amp; Kreislauferkrankungen - Deutsches Herzzentrum München</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Hengstenberg, Prof, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sabine Bleiziffer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Catania, Ferrarotto Hospital</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corrado Tamburino, Prof, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Davide Capodanno, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano- (MI)</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Pagnotta, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Bernhard Reimers, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato</city>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Bedogni, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>San Raffaele</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Colombo, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramiro Trillo-Nouche, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brighton and sussex University hospital NHS trust</name>
      <address>
        <city>Brighton</city>
        <state>England</state>
        <zip>BN25BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Hildick-Smith, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

